← All trials
NCT00165178
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2000
- Primary completion
- Dec 1, 2004
- Completion date
- May 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 498
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- University of RochesterCollaborator
- McMaster UniversityCollaborator
- Ochsner Health SystemCollaborator
- Laval UniversityCollaborator
- Columbia UniversityCollaborator
- University of MontrealCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Maine Children's Cancer ProgramCollaborator
- San Jorge Children's Hospital, Puerto RicoCollaborator
- Tulane UniversityCollaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.